1-4 of 4
William Canovatchel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study

Lawrence A. Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A. Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger
Journal: Diabetes Care
Diabetes Care 2015;38(3):355–364
https://doi.org/10.2337/dc13-2762
Published: 09 September 2014
View article titled, Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
Open the PDF for Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study in another window
Includes: Supplementary data
Journal Articles

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: A 52-week randomized trial

Guntram Schernthaner, MD, Jorge L. Gross, MD, Julio Rosenstock, MD, Michael Guarisco, MD, Min Fu, MS, Jacqueline Yee, MS, Masato Kawaguchi, MD, William Canovatchel, MD, Gary Meininger, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2508–2515
https://doi.org/10.2337/dc12-2491
Published: 13 August 2013
View article titled, Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: <subtitle>A 52-week randomized trial</subtitle>
Open the PDF for Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea: <subtitle>A 52-week randomized trial</subtitle> in another window
Includes: Supplementary data
Journal Articles

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Julio Rosenstock, MD, Naresh Aggarwal, MD, David Polidori, PHD, Yue Zhao, PHD, Deborah Arbit, MD, Keith Usiskin, MD, George Capuano, PHD, William Canovatchel, MD, for the Canagliflozin DIA 2001 Study Group
Journal: Diabetes Care
Diabetes Care 2012;35(6):1232–1238
https://doi.org/10.2337/dc11-1926
Published: 11 May 2012
View article titled, Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
Open the PDF for Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study

Priscilla A Hollander, MD, PHD, Steven C Elbein, MD, Irl B Hirsch, MD, David Kelley, MD, Janet McGill, MD, Terry Taylor, MD, Stuart R Weiss, MD, Samuel E Crockett, MD, Roy A Kaplan, MD, John Comstock, MD, Charles P Lucas, MD, Peter A Lodewick, MD, William Canovatchel, MD, Jain Chung, MD, Jonathan Hauptman, MD
Journal: Diabetes Care
Diabetes Care 1998;21(8):1288–1294
https://doi.org/10.2337/diacare.21.8.1288
Published: 01 August 1998
View article titled, Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study
Open the PDF for Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study in another window